Loading...
•
Mar 31, 2020
Viridian Therapeutics Q1 2020 Earnings Report
Reported first quarter financial results and provided a corporate update.
Key Takeaways
miRagen Therapeutics reported $36.1 million in cash and cash equivalents as of March 31, 2020, with an anticipated cash runway into Q3 2021. The company's net loss was $8.0 million, or $0.18 per share, for the first quarter of 2020.
New ATLL data was presented, and the company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020.
Additional NIH grant funding was released in support of MRG-229 for IPF, with preclinical studies progressing as planned and additional data expected in Q2 2020.
The SOLAR trial has been impacted by the COVID-19 pandemic, with patient monitoring and dosing suspended at some sites.
A $15.0 million equity offering was closed in February 2020.
Revenue by Segment
Forward Guidance
miRagen believes that its current cash and cash equivalents will be sufficient to fund the Company’s operations into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...